EWA
BCLI

EverSource Wealth Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

EverSource Wealth Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-141
Closed -$320 – 4039
2024
Q4 		$320 Buy
+141
New +$260 ﹤0.01% 3327
2024
Q3 		– Sell
-142
Closed -$728 – 3038
2024
Q2 		$728 Hold
142
– – ﹤0.01% 2800
2024
Q1 		$803 Hold
142
– – ﹤0.01% 2637
2023
Q4 		$581 Buy
+142
New +$426 ﹤0.01% 2500

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EverSource Wealth Advisors's BCLI Position: Q1 2025 in Review

EverSource Wealth Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 141 shares — an estimated $320 sold.

EverSource Wealth Advisors first reported a position in BCLI in Q4 2023 and held it in 4 quarters. The position peaked at $803 in Q1 2024. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

  • EverSource Wealth Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 141 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $320.
  • EverSource Wealth Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2023 and held it in 4 quarters.
  • EverSource Wealth Advisors's BRAINSTORM CELL THERAPUTC position peaked at $803 in Q1 2024.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on EverSource Wealth Advisors's 13F filing for Q1 2025, filed 13 May 2025.